+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial



ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial



Journal of Clinical Oncology 20(9): 2240-2250



To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors. This was an open, phase I, escalating multiple-dose tolerability and pharmacokinetic trial. ZD1839 was administered once daily for 14 consecutive days followed by 14 days off treatment. Dose escalation started at 50 mg/d and continued to 925 mg or until consistent dose-limiting toxicity (DLT) was observed. Sixty-four patients were entered at eight dose levels. The most frequent dose-related grade 1 and 2 adverse events were an acne-like (or folliculitis) rash, nausea, and diarrhea. Three of nine patients treated at 700 mg/d developed DLT (reversible grade 3 diarrhea); grade 3 and 4 events were uncommon. Exposure to ZD1839 was dose proportional, and the mean terminal half-life was 48 hours (range, 37 to 65). Four of 16 patients with non-small-cell lung cancer (NSCLC) had objective partial responses observed from ZD1839 300 to 700 mg/d. Overall, 16 patients remained on study for > or = 3 months, with seven of these patients (five with NSCLC, including three of the patients with partial response) remaining on study for > or = 6 months. ZD1839 was well tolerated, with DLT observed at a dose well above that at which antitumor activity was seen. Pharmacokinetic analysis confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation. Phase II monotherapy and phase III combination trials in NSCLC are being conducted to investigate further the efficacy, tolerability, and optimal daily dose of ZD1839.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047991599

Download citation: RISBibTeXText

PMID: 11980995

DOI: 10.1200/jco.2002.10.112


Related references

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology 20(18): 3815-3825, 2002

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Annals of Oncology 14(6): 922-930, 2003

ZD1839 , an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor , is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours Preliminary tolerability, efficacy and pharmacokinetic results. European Journal of Cancer 37(Suppl. 6): S30-S31, 2001

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of Clinical Oncology 20(21): 4292-4302, 2002

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clinical Cancer Research 9(6): 2040-2048, 2003

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational new Drugs 23(2): 165-170, 2005

ZD1839 , an oral epidermal growth factor receptor tyrosine kinase inhibitor Pharmacokinetics in a phase I study of patients with advanced cancer. Proceedings of the American Association for Cancer Research Annual Meeting (41): 612-613, 2000

A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1002, 2002

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye 19(7): 729-738, 2005

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clinical Pharmacokinetics 40(4): 297-306, 2001

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer ChemoTherapy and Pharmacology 61(3): 489-496, 2008

Oral administration of the specific epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is efficacious against EGFR-overexpressing intracranial tumors. Proceedings of the American Association for Cancer Research Annual Meeting 43: 785, 2002

Pilot trials of ZD1839 , an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. Journal of Urology 169(4 Suppl.): 244, 2003

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic and Medicinal Chemistry Letters 11(14): 1911-1914, 2001

The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib , is an active agent in bronchioloalveolar carcinoma and its variants Interim results of a Phase II trial. EJC Suppl.s 1(5): S21, 2003